Early Postoperative Intraperitoneal Chemotherapy for Macroscopically Serosa-Invading Gastric Cancer Patients.
- Author:
Oh Kyoung KWON
1
;
Ho Young CHUNG
;
Wansik YU
Author Information
1. Gastric Cancer Center, Kyungpook National University Medical Center, Daegu, Korea. wyu@knu.ac.kr
- Publication Type:Original Article
- Keywords:
Stomach neoplasm;
Adjuvant chemotherapy;
Locoregional neoplasm reccurence
- MeSH:
Chemotherapy, Adjuvant;
Daegu;
Drug Therapy*;
Gyeongsangbuk-do;
Humans;
Korea;
Lymph Nodes;
Mortality;
Multivariate Analysis;
Neoplasm Metastasis;
Prognosis;
Recurrence;
Stomach Neoplasms*;
Survival Rate
- From:Cancer Research and Treatment
2014;46(3):270-279
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Peritoneal recurrence is one of the most common patterns of recurrence after gastric cancer surgery and it has a poor prognosis despite all efforts. The aim of this study is to evaluate the prognostic impact of early postoperative intraperitoneal chemotherapy (EPIC) after surgery with curative intent for macroscopically serosa-invading gastric cancer patients. MATERIALS AND METHODS: The records of 245 patients under the age of 70 were reviewed. These patients were suffering from macroscopically seroa-invading gastric cancer and they underwent curative surgery from 1995 to 2004 at the Kyungpook National University Hospital, Daegu, Korea. The overall survival, gastric cancer-specific survival, complications, and patterns of recurrence were compared between the patients who were treated with EPIC and those who were not. RESULTS: EPIC was administered to 65 patients, and the remaining 180 patients did not receive this treatment. The 5-year overall and gastric cancer-specific survival rates for the EPIC group were 47.4% and 53.1%, respectively, and those for the non-EPIC group were 26.7% and 29.7%, respectively (p=0.012 for overall survival and p=0.011 for gastric cancer-specific survival). The rates of peritoneal recurrence for the EPIC group and the non-EPIC group were 18.5% and 32.2%, respectively (p=0.038). There were no significant differences in the morbidity or mortality between the two groups. Based on a multivariate analysis of the factors with prognostic significance in univariate analyses, EPIC, pathological lymph node metastasis, differentiation, and the extent of gastric resection were independent prognostic factors. CONCLUSION: The use of EPIC to treat gastric cancer patients with macroscopic serosal invasions resulted in better survival rate by reducing the risk of peritoneal recurrence.
